Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Sichuan Kelun Biotech (2629 HK): Sac-TMT Driving To The Core in 1H26, Pipeline Progressing Well

Equity Capital Markets

Sichuan Kelun-Biotech Biopharmaceutical / Equity Capital Markets

Sichuan Kelun-Biotech Biopharmaceutical (6990 HK)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sichuan-kelun-biotech-biopharmaceutical-co-ltd-class-h" target="_blank" data-smartkarma-citation="entities:40071:1" rel="noopener">Sichuan Kelun-Biotech Biopharmaceutical (6990 HK)</a> announced the placement of 5.8M shares for subscription at HK$470.2 per share. The placing price represents a discount of 8.5% to the undisturbed price.</li>
<li>Sichuan Kelun Biotech intends to use the proceeds majorly for research and development, enhance internal R&amp;D capabilities, strengthen external collaboration, expand its product pipeline portfolio and for working capital.</li>
<li>Kelun Biotech’s drug development skill is evidenced by the outlicensing deals it has signed, especially with Merck for sac-TMT. From commercial perspective, sac-TMT has potential to generate multi-billion-dollar revenue.</li>
</ul>



Sichuan Kelun-Biotech Biopharmaceutical (6990 HK) announced the placement of 5.8M shares for subscription at HK$470.2 per share. The placing price represents a discount of 8.5% to the undisturbed price.
Sichuan Kelun Biotech intends to use the proceeds majorly for research and development, enhance internal R&amp;D capabilities, strengthen external collaboration, expand its product pipeline portfolio and for working capital.
Kelun Biotech’s drug development skill is evidenced by the outlicensing deals it has signed, especially with Merck for sac-TMT. From commercial perspective, sac-TMT has potential to generate multi-billion-dollar revenue.


Sichuan Kelun Biotech (2629 HK) Placement: To Fund R&D; Sac-TMT Is Getting Ready for Global Take-Off